13th May 2016 10:18
LONDON (Alliance News) - GlaxoSmithKline PLC said its Bexsero meningitis vaccine met its primary and secondary endpoints in a phase IIIb study in infants and young children with a reduced dose schedule.
In new data presented at the annual meeting for the European Society for Paediatric Infectious Disease,s the study met its primary and secondary endpoints, showing comparable immune response and safety in infants receiving a reduced schedule of two primary doses of Bexsero, plus a booster dose, compared to those receiving the current European Union approved schedule of three doses plus a booster dose.
"Meningitis B is a rare but potentially devastating disease that can result in death or life-long disability. We believe that these initial study results may support a reduced dosing schedule, which could mean fewer shots for infants. We look forward to the important additional data that will come out of the UK routine infant immunisation programme with Bexsero, which may enable countries to have different scheduling options in the future," said Chief Medical Officer of Vaccines Thomas Breuer in a statement.
Shares in GlaxoSmithKline were down 0.4% at 1,435.50 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline